Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/22931
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Sentinel-node biopsy or nodal observation in melanoma |
Author: | Morton, D. Thompson, J. Cochran, A. Mozzillo, N. Elashoff, R. Essner, R. Nieweg, O. Roses, D. Hoekstra, H. Karakousis, C. Reintgen, D. Coventry, B. Glass, E. Wang, H. |
Citation: | New England Journal of Medicine, 2006; 355(13):1307-1317 |
Publisher: | Massachusetts Medical Soc |
Issue Date: | 2006 |
ISSN: | 0028-4793 1533-4406 |
Statement of Responsibility: | Donald L. Morton, M.D., John F. Thompson, M.D., Alistair J. Cochran, M.D., Nicola Mozzillo, M.D., Robert Elashoff, Ph.D., Richard Essner, M.D., Omgo E. Nieweg, M.D., Ph.D., Daniel F. Roses, M.D., Harald J. Hoekstra, M.D., Ph.D., Constantine P. Karakousis, Douglas S. Reintgen, M.D., Brendon J. Coventry, Edwin C. Glass, and He-Jing Wang, |
Abstract: | Background We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma. Methods Patients with a primary cutaneous melanoma were randomly assigned to wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected on biopsy. Results Among 1269 patients with an intermediate-thickness primary melanoma, the mean (±SE) estimated 5-year disease-free survival rate for the population was 78.3±1.6% in the biopsy group and 73.1±2.1% in the observation group (hazard ratio for death, 0.74; 95% confidence interval [CI], 0.59 to 0.93; P = 0.009). Five-year melanoma-specific survival rates were similar in the two groups (87.1±1.3% and 86.6±1.6%, respectively). In the biopsy group, the presence of metastases in the sentinel node was the most important prognostic factor; the 5-year survival rate was 72.3±4.6% among patients with tumor-positive sentinel nodes and 90.2±1.3% among those with tumor- negative sentinel nodes (hazard ratio for death, 2.48; 95% CI, 1.54 to 3.98; P<0.001). The incidence of sentinel-node micrometastases was 16.0% (122 of 764 patients), and the rate of nodal relapse in the observation group was 15.6% (78 of 500 patients). The corresponding mean number of tumor-involved nodes was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating disease progression during observation. Among patients with nodal metastases, the 5-year survival rate was higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3±4.6% vs. 52.4±5.9%; hazard ratio for death, 0.51; 95% CI, 0.32 to 0.81; P = 0.004). Conclusions The staging of intermediate-thickness (1.2 to 3.5 mm) primary melanomas according to the results of sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases whose survival can be prolonged by immediate lymphadenectomy. (ClinicalTrials.gov number, NCT00275496.) |
Keywords: | MSLT Group Lymph Nodes Humans Melanoma Skin Neoplasms Lymphatic Metastasis Neoplasm Recurrence, Local Disease Progression False Negative Reactions Sentinel Lymph Node Biopsy Neoplasm Staging Prognosis Disease-Free Survival Lymph Node Excision Survival Rate Middle Aged Female Male |
Description: | Copyright © 2006 Massachusetts Medical Society |
DOI: | 10.1056/NEJMoa060992 |
Published version: | http://content.nejm.org/cgi/content/abstract/355/13/1307 |
Appears in Collections: | Aurora harvest 2 Surgery publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.